1. [Malignant lymphoma associated with HIV infection].
- Author
-
Mitrou PS, Serke M, Pohl C, Becker K, Schrappe-Bächer M, Knauf W, Westerhausen M, Clemens MR, Helm EB, and Fischer T
- Subjects
- Adult, Aged, Antineoplastic Agents therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Combined Modality Therapy, Cyclophosphamide therapeutic use, Doxorubicin therapeutic use, Female, HIV Seropositivity complications, Hodgkin Disease etiology, Humans, Lymphoma therapy, Lymphoma, Non-Hodgkin etiology, Lymphoma, Non-Hodgkin therapy, Male, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma etiology, Prednisone therapeutic use, Prognosis, Retrospective Studies, Vincristine therapeutic use, HIV Infections complications, Lymphoma etiology
- Abstract
The course of disease in 119 HIV-infected patients (117 men, 2 women; median age 38.5 years) with malignant tumours other than Kaposi's sarcoma was analyzed in a multi-centre retrospective study. This was conducted to obtain initial information concerning the incidence, clinical features and results of therapy in HIV-associated neoplasms, especially malignant lymphomas. The most frequent tumour was malignant non-Hodgkin's lymphoma (98 patients, 82.5%), seven patients had Hodgkin's disease, five had solid tumours, four a polyclonal lymphoproliferative syndrome, three an acute lymphocytic leukaemia, and two had other lymphoproliferative diseases. 58% of the non-Hodgkin's lymphomas occurred in patients with marked immunodeficiency, 85% were high grade malignancies and 47% had primary extranodal disease. 56% of primary nodal lymphomas also had visceral spread (Stage IV). Lymphoblastic non-Hodgkin's lymphoma was more common in patients with favourable immunological status, presented less frequently with primary extranodal disease, was diagnosed earlier than other non-Hodgkin's lymphomas, and appeared to carry a better prognosis. 78 out of the 98 patients with non-Hodgkin's lymphoma had been treated, 66 with cytotoxics. The median survival time was 6 months. Longer remission periods, of at least 12 months, were seen in ten of the 78 patients (13%). Despite the overall poor prognosis and the pre-existing immune defect, palliative (chemo-)therapeutic measures are both justified and promising, and may also result in life-prolonging remissions.
- Published
- 1991
- Full Text
- View/download PDF